P016 A model for targeting weight loss therapy in OSA treatment

P016 针对OSA治疗中体重减轻疗法的模型

阅读:1

Abstract

INTRODUCTION: Obstructive sleep apnoea (OSA) is a heterogeneous disorder characterised by repeated upper-airway collapse during sleep. Given the major role of obesity in OSA pathogenesis, weight loss is commonly a recommended therapy, though its effectiveness can be highly variable. As weight loss therapies often require considerable time, effort, or cost, better tools are needed to identify likely responders and enable timely, targeted treatment decisions. METHODS: 149 adults (age[mean ± SD] = 49 ± 10) from five weight loss studies were included, all of whom achieved >5% reduction in body-mass index (BMI) following intervention. Baseline polysomnographic (PSG) metrics from clinical sleep studies were used as predictors. Two machine learning models, XGBoost and a deep neural network (DNN), were implemented to predict 1) a > 50% reduction in apnoea–hypopnoea index (AHI), and 2) a categorical improvement in OSA severity (e.g., from moderate to mild). Models were trained on ~80% of the sample and tested on the remaining 20%. RESULTS: For predicting a > 50% reduction in AHI, both models showed moderate accuracy (XGBoost: 69%; DNN: 66%), with higher negative (79%/73%) than positive (60%/57%) predictive values. For predicting categorical improvement, overall accuracy was lower (59%/52%), though positive predictive values remained stronger (70%/60% vs. 53%/47%). DISCUSSION: Models using routine PSG data were modestly effective at predicting OSA response to weight loss, particularly in identifying non-responders. While this suggests potential utility for triaging patients, performance was more limited than models for other OSA treatments. Consequently, there may be need for additional features such as behavioural, metabolic, or phenotypic markers to improve future prediction.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。